Table 1.
Baseline characteristics of patients with non-responsive iMN in RTX/TAC and TAC groups
| Patients | RTX/TAC | TAC | P value |
|---|---|---|---|
| Female/Total (n) | 7/26 | 10/41 | 0.744 |
| Age (years) (mean ± SD) | 41.73±14.89 | 44.34±10.57 | 0.404 |
| History (months) [median (IQR)] | 22.43 (12.4-24.9) | 19.95 (12.7-21.9) | 0.128 |
| Diabetes mellitus/Total (n) | 3/26 | 6/41 | 0.999 |
| Prior immunosuppressive therapy (n) (%) | |||
| 1 | 7 (26.9%) | 20 (48.8%) | 0.770 |
| 2 | 9 (34.6%) | 12 (29.3%) | 0.788 |
| ≥3 | 10 (38.5%) | 9 (22.0%) | 0.172 |
| Previous therapies | |||
| Prednisone + cyclophosphamide, n | 26 | 41 | |
| Prednisone + cyclosporine, n | 2 | 3 | |
| Prednisone + tacrolimus, n | 6 | 2 | |
| Mycophenolate mofetil, n | 7 | 13 | |
| Prednisone + leflunomide, n | 8 | 6 | |
| Immunoglobulin G infusion, n | 9 | 11 | |
| Systolic blood pressure (mean ± SD) | 132.94±14.23 | 128.70±14.41 | 0.349 |
| Diastolic blood pressure (mean ± SD) | 86.77±9.35 | 82.98±9.83 | 0.122 |
| Proteinuria (g/24 h) (mean ± SD) | 5875.31±1548.62 | 5580.43±1510.02 | 0.441 |
| Circulation B cells (mean ± SD) | 219.2±112.91 | 208.7±49.39 | 0.607 |
| Albumin (g/L) (mean ± SD) | 25.07±5.56 | 25.85±5.92 | 0.592 |
| eGFR (mL/min/1.73 m2) (mean ± SD) | 94.23±24.67 | 88.48±19.75 | 0.324 |
| Creatinine (umol/L) (mean ± SD) | 84.50±21.62 | 84.39±22.74 | 0.984 |
| Cholesterol (mmol/l) (mean ± SD) | 6.13±1.67 | 7.05±2.06 | 0.424 |
| PLA2R positive/Total (pathology) (%) | 24/26 (92.3) | 36/41 (87.8) | 0.697 |
| PLA2R positive/Total (plasma) (%) | 18/26 (69.2) | 31/41 (75.6) | 0.584 |
| Tacrolimus initial dose (mg) | 1.41±0.36 | 2.48±0.47 | 0.01 |
| Diuretics, n (%) | 7/26 (26.9) | 12/41 (29.3) | 0.997 |
| Previous remission, n (%) | 14/26 (53.8) | 26/41 (63.4) | 0.456 |
eGFR: Estimated glomerular filtration rate; P value <0.05 statistically significant; RTX: Rituximab; TAC: Tacrolimus.